Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug‐testing and law enforcement

Author:

Copeland Caroline S.12ORCID,Rice Kathleen3,Rock Kirsten L.1ORCID,Hudson Simon4,Streete Peter5,Lawson Alexander J.6,Couchman Lewis7,Holland Adam8,Morley Stephen23

Affiliation:

1. Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science King's College London London UK

2. National Programme on Substance Abuse Deaths London UK

3. Toxicology Unit, Leicester Royal Infirmary Leicester UK

4. LGC Limited Ely UK

5. Toxicology Department Hampshire Scientific Services Hampshire UK

6. Department of Toxicology Birmingham Heartlands Hospital Birmingham UK

7. Analytical Services International Limited, St George's University of London London UK

8. School of Psychological Sciences University of Bristol Bristol UK

Abstract

AbstractBackground and aimsXylazine is a non‐opioid sedative which has spread rapidly throughout the US illicit drug supply. This study aimed to describe the spread of xylazine throughout the UK illicit drug supply.MethodsXylazine detections in human biological samples were collated from toxicology laboratories operating in the United Kingdom with the date, location, case type, xylazine concentration and co‐detected drugs (with quantifications where performed) detailed, where permitted, by the corresponding coroner. Drug‐testing cases positive for xylazine were collated from the Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) drug‐testing postal service with the date, location, purchase intent and co‐detected drugs detailed. Drug seizures made by UK law enforcement were communicated by the Office for Health Improvement and Disparities with the date and location detailed.ResultsBy the end of August 2023, xylazine was detected in 35 cases from throughout toxicology, drug‐testing and drug seizure sources covering England, Scotland and Wales. There were no cases reported from Northern Ireland. Xylazine was detected in biological samples from 16 people. In most cases where full toxicology results were provided, xylazine was detected with heroin and/or a strong opioid (n = nine of 11), but this polydrug use pattern was not evident in all cases (n = two of 11), suggesting a wider circulation of xylazine in the UK illicit drug market beyond heroin supplies. Evidence from WEDINOS supports this claim, as all 14 drug samples (100%) submitted from across the UK contained xylazine; however, in none of these cases was heroin the purchase intent but rather counterfeit prescription medication tablets (n = 11 of 14), tetrahydrocannabinol (THC) vapes (n = two of 14) or white powder (n = one of 14). Additional evidence for the spread of illicit xylazine comes from five drug seizures made by law enforcement.ConclusionsXylazine has penetrated the UK illicit drug market and is not limited to heroin supplies.

Publisher

Wiley

Reference15 articles.

1. Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework

2. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis

3. GuptaR.Biden‐Harris administration designates fentanyl combined with xylazine as an emerging threat to the United States [press release]. Washington DC: The White House;2023. Available at:https://www.whitehouse.gov/ondcp/briefing‐room/2023/04/12/biden‐harris‐administration‐designates‐fentanyl‐combined‐with‐xylazine‐as‐an‐emerging‐threat‐to‐the‐united‐states/#:~:text=By%20declaring%20xylazine%20combined%20with and%20communities%20across%20the%20Nation(accessed August 2023).

4. The first drug-related death associated with xylazine use in the UK and Europe

5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).The drug situation in Europe up to 2023—an overview and assessment of emerging threats and new developments (European Drug Report 2023). Lisbon Portugal: EMCDDA;2023. Available at:https://www.emcdda.europa.eu/publications/european-drug-report/2023_en(accessed January 2024).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3